Directs role of CRP in promoting pathogenesis of atherosclerosis through up-regulation of proinflammatory cytokines

Print Friendly, PDF & Email
AJBM  Volume 2, Issue 2, pages 238–244, February 2014                Full Text-PDF 
 

Julian J Steg, Hanan Slimani, Tennent K Hanley, Baron D Pearson, and Mandel Z Manson

Abstract

Recent research suggests that patients with elevated basal levels of CRP are at an increased risk of diabetes, hypertension and cardiovascular disease, and an important risk factor for atherosclerosis. CRP is an acute-phase reactant usually present in human serum with a concentration is usually lower than 10 mg/L, slightly increasing with aging. Higher levels are found in late pregnant women, mild inflammation and viral infections (10–40 mg/L), active inflammation, bacterial infection (40–200 mg/L), severe bacterial infections and burns (>200 mg/L). Experiments were performed on human vascular endothelial cells. That are incubated with human CRP for the indicated time, and proinflammatory cytokines, chemokines and adhesion molecule expression were detected by flow cytometry, ELIZA and western blot respectively. Human vascular endothelial cells cultured with recombinant CRP (15 μg/mL for 48 hours) showed increase in ICAM-1, VCAM-1, IL-6, 1L-1B, TNF-α and MCP-1. We concluded that CRP may play a direct role in promoting the proinflammatory component of atherosclerosis and present a potential target for the treatment of atherosclerosis.

Key words: Atherosclerosis, CRP, Proinflammatory cytokines, Cell adhesion molecules 


References

1. Nilsson J. CRP–marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005;25:1527–1528. [PubMed]

2. Gu L, Okada Y, Clinton S, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein-deficient mice. Mol Cell 1998; 2: 275–281. [Medline]

3. Wang J, Juan JD, Miravalle DH, Kudva RI, Swamy CL, Mair TP, Johansen L, et al. Role of macrophage SR-BI class a scavenger receptor in atherosclerosis: crosstalk TLR4/NF-KB/ signaling pathway activation. American journal of BioMedicine 2014;2(1):94-112. [Abstract/Full-Text]  

4. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–1812. [PubMed]

5. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165–2168. [Abstract/FREE Full Text]

6. Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005;167:1139–1148. [PubMed]

7. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647–655. [PubMed

8. Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM, Emeis JJ. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 2005;25:1635–1640. [PubMed]

9. Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M, Blettner M, Bhakdi S. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol. 2005;25:1641–1646. [PubMed]

10. NG Yousif, J Li, Yousif F, Ao L, Jin, Fullerton DA, Dinarello CA, Meng X. Expression of Human Interleukine-37 Protects Mouse Heart Against Ischemic Injury Through Suppression of Monocyte Chemoattractant Protein-1-Mediated Mononuclear Cell Accumulation. CIRCULATION 2011;24(21). [Google Scholar]

11. Anderson HC, Mc CM. The occurrence in the rabbit of an acute phase protein analogous to human C reactive protein. J Exp Med 1951;93:25–36. [PubMed]

12. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897–1908. [PubMed]

13. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565. [PubMed]

14. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003;108:512–515. [PubMed]

15. Potte JB, Hinojoza VR, Pamela C, Lavandero N. Protective effects of Curcumin against development of atherosclerosis. American journal of BioMedicine 2014;2(1):132-145. [Abstract/Full-Text]  

16. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868–74. [CrossRef]  

17. Kim HG,Shrestha B,Lim SY,Yoon DH,Chang WC,Shin DJ,Han SK, et al. Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-kappaB through Akt and p38 inhibition in RAW 264.7 macrophage cells. Eur J Pharmacol 2006;545:192–9. [Medline]

18. Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, Xiao X, Tall AR. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001;7:847–52. [CrossRef]

19. Zhai Y, Ao L, Yousif NG, Al-amran F, Fullerton D, Meng X .TLR4 mediates the inflammatory response of remote non-ischemic myocardium and contributes to heart failure in a mouse model of myocardial infarction. SHOCK 2013; 39;29. [CrossRef]

20. Cheung MC, Wolfbauer G, Kennedy H, Brown BG, Albers JJ. Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. Biochim Biophys Acta 2001;1537:117–24. [Medline]

21. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005;1:121–31. [CrossRef]

22. Li YD, Ye BQ, Zheng SX, Wang JT, Wang JG, Chen M, Liu JG, Pei XH, Wang LJ, Lin ZX, Gupta K, Mackman N, Slungaard A, Key NS, Geng JG. NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem 2009;284:4473–83. [FREE Full Text]

23. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA. 2004;101:9774–9779. [PubMed]

24. Qin S, Koga T, Ganji SH, Kamanna VS, Kashyap ML. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. Metabolism. 2008;57:973–979. [PubMed] [Cross Ref]

25. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D. et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115–121. [PubMed]

26. Choudhury RP, Carrelli AL, Stern JD, Chereshnev I, Soccio R, Elmalem VI, Fallon JT, Fisher EA, Reis ED. Effects of simvastatin on plasma lipoproteins and response to arterial injury in wild-type and apolipoprotein-E-deficient mice. J Vasc Res. 2004;41:75–83. [Cross Ref]

27. Ly H, Francone OL, Fielding CJ, Shigenaga JK, Moser AH, Grunfeld C, Feingold KR. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J Lipid Res. 1995;36:1254–1263. [PubMed]

28. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci. 2008;82:708–717. [PubMed] [Cross Ref]

29. Ramote D, Kishony J, Bren L. Role  of monocyte chemoattractant protein-1 (MCP-1) in atherosclerosis: Signature of monocytes and macrophages. American journal of BioMedicine 2014;2(1):67-79. [Abstract/Full-Text]

30. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161-171. [Google Scholar]

31. Marleau S, Harb D, Bujold K, Avallone R, Iken K, Wang Y, et al . EP 80317 a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J 2005;19:1869-1871. [Abstract/Full-Text]

32. Tall AR, Costet P, Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest 2002;110:899-904. [Medline]

33. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, et al. Macrophage ABCA1 ABCG1, but not SR-BI promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007;117:2216-2224. [Medline]

34. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002;90:844-849. [Abstract/Full-Text]

35. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 2002;277:38503-38516. [Abstract/Full-Text]

36. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115-126. [CrossRef]

37. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, Steffens S, Mach F. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis. 2006;188:51–58. [Medline]

38. Argmann CA, Edwards JY, Sawyez CG, O’Neil CH, Hegele RA, Pickering JG, Huff MW. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition. J Biol Chem. 2005;280:22212–22221. [Abstract/Full-Text

39. Ståhlman M, Pham HT, Adiels M, Mitchell TW, Blanksby SJ, Fagerberg B, Ekroos K,
Borén J. Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes. Diabetologia. 2012;55:1156–1166. [
Medline]

40. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, et al. LA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 2000;101:2411–2417. [Abstract/FREE Full Text]

American Journal of Biomedicine © 2019 BM-Publisher
%d bloggers like this: